Natera Tech in 300+ Studies Highlights Precision Medicine Leadership
Natera, Inc. (NASDAQ: NTRA), a world chief in cell-free DNA testing and precision medication, right this moment introduced the publication of greater than 300 peer-reviewed papers that includes its know-how and reinforcing its long-standing dedication to sturdy medical proof and scientific analysis. These publications span high-impact journals – corresponding to Nature, Nature Medication, the American Journal of Transplantation and American Journal…
